These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31883678)

  • 1. Usefulness of High-Sensitivity Troponin I to Predict Outcome in Patients With Newly Detected Atrial Fibrillation.
    Kim BS; Kwon CH; Chang H; Kim SH; Kim HJ; Hwang HK; Chung SM
    Am J Cardiol; 2020 Mar; 125(5):744-750. PubMed ID: 31883678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
    Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
    Jia X; Sun W; Hoogeveen RC; Nambi V; Matsushita K; Folsom AR; Heiss G; Couper DJ; Solomon SD; Boerwinkle E; Shah A; Selvin E; de Lemos JA; Ballantyne CM
    Circulation; 2019 Jun; 139(23):2642-2653. PubMed ID: 31030544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of cardiac troponin and cardiovascular events in patients with concomitant heart failure preserved ejection fraction and atrial fibrillation.
    Kim BS; Kwon CH; Chang H; Choi JH; Kim HJ; Kim SH
    BMC Cardiovasc Disord; 2023 May; 23(1):273. PubMed ID: 37226163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of High-Sensitivity Troponin I with Cardiac and Cerebrovascular Events in Patient after Ischemic Stroke.
    Kim BS; Park JJ; Chang H; Kim SH; Kwon CH; Chung SM; Kim HY; Kim HJ
    Cerebrovasc Dis; 2023; 52(2):153-159. PubMed ID: 35908539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease.
    Sandesara PB; O'Neal WT; Tahhan AS; Hayek SS; Lee SK; Khambhati J; Topel ML; Hammadah M; Alkhoder A; Ko YA; Gafeer MM; Beshiri A; Murtagh G; Kim JH; Wilson P; Shaw L; Epstein SE; Sperling LS; Quyyumi AA
    Am J Cardiol; 2018 Jun; 121(12):1461-1466. PubMed ID: 29628129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health [HUNT] Study).
    Sigurdardottir FD; Lyngbakken MN; Holmen OL; Dalen H; Hveem K; Røsjø H; Omland T
    Am J Cardiol; 2018 Apr; 121(8):949-955. PubMed ID: 29496193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.
    Fudim M; Ambrosy AP; Sun JL; Anstrom KJ; Bart BA; Butler J; AbouEzzeddine O; Greene SJ; Mentz RJ; Redfield MM; Reddy YNV; Vaduganathan M; Braunwald E; Hernandez AF; Borlaug BA; Felker GM
    J Am Heart Assoc; 2018 Dec; 7(24):e010364. PubMed ID: 30561266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of troponin I in atrial fibrillation.
    Quesada A; López-Valero L; Marcaida-Benito G; Bello JJ; Quesada-Ocete J; Rubini-Costa R; Quesada-Ocete B; Rubini-Puig R; Férez-Martí A; Del Moral-Ronda V; Palanca-Gil V; de la Guía-Galipienso F; Lavie CJ; Lippi G; Sanchis-Gomar F
    Prog Cardiovasc Dis; 2021; 67():80-88. PubMed ID: 33639172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population.
    Horjen AW; Ulimoen SR; Enger S; Berge T; Ihle-Hansen H; Norseth J; Tveit A
    Scand J Clin Lab Invest; 2015 Jul; 75(4):308-13. PubMed ID: 25761493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between cardiac troponin I and mortality in patients with COVID-19.
    Salvatici M; Barbieri B; Cioffi SMG; Morenghi E; Leone FP; Maura F; Moriello G; Sandri MT
    Biomarkers; 2020 Dec; 25(8):634-640. PubMed ID: 33003961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.
    Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
    J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic value of a careful symptom evaluation and high sensitive troponin in patients with suspected stable angina pectoris without prior cardiovascular disease.
    Madsen DM; Diederichsen ACP; Hosbond SE; Gerke O; Mickley H
    Atherosclerosis; 2017 Mar; 258():131-137. PubMed ID: 28031149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing.
    Horjen AW; Ulimoen SR; Enger S; Norseth J; Seljeflot I; Arnesen H; Tveit A
    BMC Cardiovasc Disord; 2016 May; 16():79. PubMed ID: 27142292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The limited prognostic role of echocardiograms in short-term follow-up after acute decompensated heart failure: An analysis of the Korean Heart Failure (KorHF) Registry.
    Kim SH; Kim HJ; Han S; Yoo BS; Choi DJ; Kim JJ; Jeon ES; Cho MC; Chae SC; Ryu KH
    PLoS One; 2017; 12(12):e0188938. PubMed ID: 29261675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Prognostic Significance of High-Sensitive Troponin I Increase during Hospital Stay in Patients with Acute Myocardial Infarction and Non-Obstructive Coronary Arteries.
    Jędrychowska M; Januszek R; Wańha W; Malinowski KP; Kunik P; Trznadel A; Bartuś J; Staszczak B; Januszek SM; Kameczura T; Wojakowski W; Surdacki A; Bartuś S
    Medicina (Kaunas); 2020 Aug; 56(9):. PubMed ID: 32867290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.